Tango Therapeutics (TNGX) – Research Analysts’ Weekly Ratings Changes

Tango Therapeutics (NASDAQ: TNGX) recently received a number of ratings updates from brokerages and research firms:

• 6/8/2026 – Tango Therapeutics was given a new $36.00 price target by Mizuho.
• 6/8/2026 – Tango Therapeutics was given a new $35.00 price target by Wolfe Research.
• 6/8/2026 – Tango Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 6/8/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $55.00 to $69.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Tango Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”.
• 5/28/2026 – Tango Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/15/2026 – Tango Therapeutics had its price target raised by Mizuho from $20.00 to $30.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $24.00 price target on the stock, up from $16.00.
• 5/14/2026 – Tango Therapeutics was given a new $55.00 price target by UBS Group AG.
• 5/14/2026 – Tango Therapeutics was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $27.00 price target on the stock, up from $18.00.
• 5/14/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $28.00 to $55.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics had its price target raised by Wedbush from $19.00 to $33.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Tango Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/27/2026 – Tango Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 4/27/2026 – Tango Therapeutics had its price target raised by Stifel Nicolaus from $24.00 to $40.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Tango Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Activity

In related news, insider Adam Crystal sold 38,460 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $25.00, for a total value of $961,500.00. Following the transaction, the insider directly owned 112,622 shares in the company, valued at $2,815,550. This trade represents a 25.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 131,460 shares of company stock valued at $2,965,920. 6.50% of the stock is owned by company insiders.

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.